

Leukaemia – A list that is worth reading!

Have you ever faced the situation where you go to PubMed to read on a topic you are interested in? Often the only thing you want is to search your keywords and get the article that you are looking for without the hassle of going through a few hits. But in reality, you need to change your keywords in order to find the most relevant articles on your topics.

Here in **Rarity Bioscience**, one of my favourite topics is **Leukemia**, and that is not only for literature! This is why we put a list of our favourite articles together and would like to share it with you. Hope you also enjoy reading them:

Subject: AML

Title: Acute myeloid leukaemia

Summary: A recent review on new clinical and diagnostic approaches in AML. With an overview on risk classification based on European LeukemiaNet 2022 classification and the role of MRD in relapse.

Journal & Year: Lancet. 2023

PubMed Link: <https://pubmed.ncbi.nlm.nih.gov/37068505/>

Subject: AML therapy

Title: Molecularly Targeted Therapy in Acute Myeloid Leukemia: Current Treatment Landscape and Mechanisms of Response and Resistance

Summary: A recent review on targeted therapy in AML with a focus on *FLT3* and *IDH 1/2* mutations.

Journal & Year: Cancers. 2023

PubMed Link: <https://pubmed.ncbi.nlm.nih.gov/36900407/>

Subject: AML/MRD

Title: Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel

Summary: Key recommendation from European LeukemiaNet (ELN)-DAVID AML MRD working group on measurable residual disease (MRD) assessment and assay selection for Molecular MRD assessment.

Journal & Year: Am J Hematol. 2023

PubMed Link: <https://pubmed.ncbi.nlm.nih.gov/37671649/>

Subject: AML

Title: Unified classification and risk-stratification in Acute Myeloid Leukemia

Summary: Molecular classification for an AML patient's cohort to create a prognostic decision model based on patients' clinical data.

Journal & Year: Nat Commun. 2022

PubMed Link: <https://pubmed.ncbi.nlm.nih.gov/35941135/>

Subject: MRD

Title: Understanding differential technologies for detection of MRD and how to incorporate into clinical practice

Summary: A case study report for MRD monitoring from diagnosis until relapse based on European LeukemiaNet (ELN)22 guidelines.

Journal & Year: Hematology Am Soc Hematol Educ Program. 2023

PubMed Link: <https://pubmed.ncbi.nlm.nih.gov/38066915/>

Subject: AML

Title: Analysis of rare driving events in pediatric acute myeloid leukemia

Summary: A study on pediatric AML cohort with next-generation sequencing, gene expression analysing, and NPM1 immunofluorescence.

Journal & Year: Haematologica. 2023

PubMed Link: <https://pubmed.ncbi.nlm.nih.gov/35899387/>

Subject: AML

Title: Prognostic Value of *FLT3*-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia

Summary: Study on a patient cohort for de novo *FLT3-ITD* AML as a MRD marker with next-generation sequencing and multiparameter flow cytometry.

Journal & Year: J Clin Oncol. 2023

PubMed Link: <https://pubmed.ncbi.nlm.nih.gov/36315929/>

Subject: MRD/ ddPCR

Title: A New View on Minimal Residual Disease Quantification in Acute Lymphoblastic Leukemia using Droplet Digital PCR

Summary: A study for MRD assessment on pediatric and adult cohorts utilising ddPCR, qPCR and flow cytometry.

Journal & Year: J Mol Diagn. 2022

PubMed Link: <https://pubmed.ncbi.nlm.nih.gov/35691569/>